Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Record Net Product Revenue Achievement
IBRX logo

ImmunityBio Achieves Record 168% Revenue Growth Driven by ANKTIVA Expansion

IBRX8-KFiling Date: 5/7/2026
ImmunityBio, Inc.
Description

What this story covers

ImmunityBio reported record Q1 2026 net product revenue of $44.2 million, a 168% year-over-year increase. Despite a large GAAP net loss due to non-cash valuation adjustments, strong gross margins and global expansion signal significant commercial momentum for its immunotherapy platform.

Story snapshot

CompanyImmunityBio, Inc.
TickerIBRX
VariantStandard detailed
Duration5:59
Filing type8-K
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0001326110-26-000057
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing8-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in